Hippocratic AI vs Recursion Pharmaceuticals

Recursion Pharmaceuticals has a disclosed valuation of $2.2B, while Hippocratic AI's valuation is not publicly available, making a direct size comparison difficult. Recursion Pharmaceuticals employs 800 people.

Hippocratic AI has raised $120M in disclosed funding across 0 known rounds. Recursion Pharmaceuticals's funding history is not publicly available.

Both Hippocratic AI and Recursion Pharmaceuticals share the same Awaira Score of 65/100. The Awaira Score is a composite metric that factors in valuation, total funding raised, company stage, employee count, and market category.

Hippocratic AI was founded by Munjal Shah in 2023. Recursion Pharmaceuticals was founded by Chris Gibson in 2013. Visit each company's profile on Awaira for a full founder biography.

Hippocratic AI: Hippocratic AI develops a safety-focused AI platform designed to address the global shortage of healthcare professionals by deploying AI agents that perform patient-facing healthcare communication tasks including care navigation, medication adherence outreach, chronic disease monitoring, and post-discharge follow-up. The platform is built around a healthcare-specific large language model with extensive safety evaluation against clinical benchmarks.\n\nThe company raised approximately 120 million USD in early rounds and has established partnerships with health systems and payers focused on reducing care gaps and improving patient engagement at scale. Hippocratic positions its AI as augmenting the healthcare workforce rather than replacing clinicians, targeting the vast volume of lower-acuity patient interactions that do not require physician judgment.\n\nThe healthcare staffing shortage is a structural problem projected to worsen over the next decade, creating durable demand for AI solutions that extend the capacity of existing clinical teams. Hippocratic AI competes with ambient clinical AI companies and general-purpose AI assistant platforms, but its narrow vertical focus on patient-facing healthcare communication and its safety-first design philosophy position it to navigate the regulatory and liability landscape that general AI platforms are less equipped to manage. Recursion Pharmaceuticals: Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion operates a proprietary laboratory automation system capable of conducting millions of experiments to map cellular and molecular responses to chemical compounds. The company has developed computational models to predict drug efficacy and safety profiles before traditional clinical testing, significantly reducing development timelines and costs. As a publicly traded company with a $2.2 billion valuation, Recursion has built partnerships with major pharmaceutical firms including Bayer and Exscientia to validate its platform's effectiveness. The company's approach focuses on rare genetic diseases and oncology, leveraging its ability to process vast biological datasets that would be impractical through conventional methods. Recursion's competitive advantage lies in its integration of wet laboratory automation with advanced machine learning analytics, enabling systematic drug discovery at scale. The company continues to expand its internal pipeline while licensing its technology to established pharma players, positioning itself as both a drug developer and a computational biology platform provider in the AI healthcare sector. Recursion combines automated laboratory systems with machine learning to systematize drug discovery at unprecedented scale and speed.

Recursion Pharmaceuticals was founded first in 2013, giving it 10 years of additional market experience. Hippocratic AI was founded later in 2023. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Hippocratic AI has approximately 50-200 employees, while Recursion Pharmaceuticals has approximately 800. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Hippocratic AI and Recursion Pharmaceuticals are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.